Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Scientific Reports|June 8, 2019
Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profilesClaudia Fredolini, Sanna Byström, Laura Sanchez-Rivera, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2024
Proteomic signatures of Alzheimer's disease and Lewy body dementias: A comparative analysisAnna Canal-Garcia, Rui M Branca, Paul T Francis, et al.
Brain : a Journal of Neurology|January 12, 2018
Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approachErika Bereczki, Rui M Branca, Paul T Francis, et al.
Thyroid : Official Journal of the American Thyroid Association|July 16, 2010
Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinomaAnastasios Sofiadis, Andrii Dinets, Lukas M Orre, et al.
The Journal of Biological Chemistry|April 16, 2013
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer diseaseZhi Tang, Erika Bereczki, Haiyan Zhang, et al.
Journal of Proteome Research|August 2, 2013
Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolismMaria Pernemalm, Luigi De Petris, Rui M Branca, et al.
Oncoimmunology|October 1, 2024
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenovirusesMichaela Feodoroff, Firas Hamdan, Gabriella Antignani, et al.
Nature Communications|November 4, 2023
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumorsJacopo Chiaro, Gabriella Antignani, Sara Feola, et al.
Nature Cancer|December 6, 2021
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanismsJanne Lehtiö, Taner Arslan, Ioannis Siavelis, et al.
EMBO Molecular Medicine|January 18, 2020
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacySean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, et al.
Pageof 3